Mycobacterium tuberculosis population structure determines the outcome of genetics-based second-line drug resistance testing

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2420-2427

  Streicher, E M ^a   Bergval, I ^b   Dheda, K ^c,d   Bottger E C ^e   Gey Van Pittius, N C ^a   Bosman, M ^f   Coetzee, G ^f   Anthony, R M ^b   Van Helden, P D ^a   Victor, T C ^a   Warren, R M ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b ROYAL TROPICAL INSTITUTE   (Netherlands)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; OFLOXACIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CONTROLLED STUDY; DNA SEQUENCE; DRUG SCREENING; GENE MUTATION; GENETIC RESISTANCE; GENETICS; GENOTYPE; GOLD STANDARD; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR CLONING; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; OUTCOME ASSESSMENT; PHENOTYPE; POPULATION STRUCTURE; PRIORITY JOURNAL; TUBERCULOSIS;

AMIKACIN; ANTITUBERCULAR AGENTS; BACTERIAL TYPING TECHNIQUES; BASE SEQUENCE; DNA GYRASE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84860161260     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05905-11     Document Type: Article

References (45)

1. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. 2008. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am. J. Respir. Crit. Care Med. 177:787-792. (Pubitemid 351490566)
2. Behr MA. 2004. Tuberculosis due to multiple strains: a concern for the patient? A concern for tuberculosis control? Am. J. Respir. Crit. Care Med. 169:554-555. (Pubitemid 38270888)
3. Blakemore R, et al. 2010. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J. Clin. Microbiol. 48:2495-2501.
4. Boehme CC, et al. 2010. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med. 363:1005-1015.
5. Bottger EC, Springer B. 2009. M. tuberculosis: drug resistance and genetic mechanisms - facts, artifacts and fallacies, p 103-121. In Kaufman SHE, Walker BD (ed), AIDS and tuberculosis: a deadly liaison. Wiley Blackwell, Berlin, Germany.
6. Calver AD, et al. 2010. Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg. Infect. Dis. 16:264-271.
7. Campbell PJ, et al. 2011. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 55:2032-2041.
8. CDC. 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb. Mortal. Wkly. Rep. 55:301-305.
9. Chakravorty S, et al. 2011. Rapid detection of fluoroquinolone-resistant and heteroresistant Mycobacterium tuberculosis by use of sloppy molecular beacons and dual melting-temperature codes in a real-time PCR assay. J. Clin. Microbiol. 49:932-940.
10. Cox HS, et al. 2008. Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis. N. Engl. J. Med. 359:2398-2400.
11. Dheda K, et al. 2010. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 375:1798-1807.
12. Dheda K, Warren RM, Zumla A, Grobusch MP. 2010. Extensively drug-resistant tuberculosis: epidemiology and management challenges. Infect. Dis. Clin. North Am. 24:705-725.
13. du Plessis DG, Warren R, Richardson M, Joubert JJ, van Helden PD. 2001. Demonstration of reinfection and reactivation in HIV-negative autopsied cases of secondary tuberculosis: multilesional genotyping of Mycobacterium tuberculosis utilizing IS6110 and other repetitive elementbased DNA fingerprinting. Tuberculosis (Edinburgh) 81:211-220. (Pubitemid 32575229)
14. Gandhi NR, et al. 2006. Extensively drug resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575-1580. (Pubitemid 44780738)
15. Hillemann D, Rusch-Gerdes S, Richter E. 2009. Feasibility of the Geno-Type MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J. Clin. Microbiol. 47:1767-1772.
16. Hofmann-Thiel S, et al. 2009. Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan. Eur. Respir. J. 33:368-374.
17. Johnson R, et al. 2010. Drug-resistant tuberculosis epidemic in the Western Cape driven by a virulent Beijing genotype strain. Int. J. Tuberc. Lung Dis. 14:119-121.
18. Kamerbeek J, et al. 1997. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J. Clin. Microbiol. 35:907-914. (Pubitemid 27146535)
19. Kaplan G, et al. 2003. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect. Immun. 71:7099-7108. (Pubitemid 37475342)
20. Kiet VS, et al. 2010. Evaluation of the MTBDRsl test for detection of second-line drug resistance in Mycobacterium tuberculosis. J. Clin. Microbiol. 48:2934-2939.
21. Ling DI, Zwerling AA, Pai M. 2008. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur. Respir. J. 32:1165-1174.
22. Meier A, et al. 1996. Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population. J. Infect. Dis. 174:354-360. (Pubitemid 26251422)
23. Musser JM. 1995. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin. Microbiol. Rev. 8:496-514.
24. National Committee for Clinical Laboratory Standards. 2003. Susceptibility testing of mycobacteria, norcardiae, and other aerobic actinomycetes: approved standard, p 1-71. NCCLS, Wayne, PA.
25. Nikolayevskyy V, et al. 2006. Differentiation of tuberculosis strains in a population with mainly Beijing-family strains. Emerg. Infect. Dis. 12:1406-1413. (Pubitemid 44455217)
26. Pillay M, Sturm AW. 2007. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin. Infect. Dis. 45:1409-1414. (Pubitemid 351411867)
27. Rinder H. 2001. Hetero-resistance: an under-recognised confounder in diagnosis and therapy? J. Med. Microbiol. 50:1018-1020. (Pubitemid 33108906)
28. Rinder H, Mieskes KT, Loscher T. 2001. Heteroresistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 5:339-345. (Pubitemid 32397584)
29. Sandgren A, et al. 2009. Tuberculosis drug resistance mutation database. PLoS Med. 6:e2.
30. Shamputa IC, et al. 2004. Genotypic and phenotypic heterogeneity among Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients. J. Clin. Microbiol. 42:5528-5536. (Pubitemid 39664332)
31. Shcherbakov D, et al. 2010. Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in-vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis. Mol. Microbiol. 70:830-840.
32. Shi R, Zhang J, Li C, Kazumi Y, Sugawara I. 2006. Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing highpressure liquid chromatography and DNA sequencing. J. Clin. Microbiol. 44:4566-4568. (Pubitemid 44937098)
33. Srivastava K, et al. 2004. Correlation of mutations detected by INNO-LiPA with levels of rifampicin resistance in Mycobacterium tuberculosis. Indian J. Med. Res. 120:100-105. (Pubitemid 39248285)
34. Streicher EM, et al. 2007. Spoligotype signatures in the Mycobacterium tuberculosis complex. J. Clin. Microbiol. 45:237-240. (Pubitemid 46106435)
35. Theron G, et al. 2011. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am. J. Respir. Crit. Care Med. 184:132-140.
36. van Rie A, et al. 2005. Reinfection and mixed infection cause changing Mycobacterium tuberculosis drug-resistance patterns. Am. J. Respir. Crit. Care Med. 172:636-642.
37. van Rie A, et al. 2000. Classification of drug-resistant tuberculosis in an epidemic area. Lancet 356:22-25.
38. van Rie A, et al. 1999. Transmission of a multidrug-resistant Mycobacterium tuberculosis strain resembling "strain W" among noninstitutionalized, human immunodeficiency virus-seronegative patients. J. Infect. Dis. 180:1608-1615.
39. Victor TC, et al. 2007. Spread of an emerging Mycobacterium tuberculosis drug-resistant strain in the Western Cape of South Africa. Int. J. Tuberc. Lung Dis. 11:195-201. (Pubitemid 46219284)
40. Warren RM, et al. 2004. Patients with active tuberculosis often have different strains in the same sputum specimen. Am. J. Respir. Crit. Care Med. 169:610-614. (Pubitemid 38270897)
41. WHO.2008. The global MDR-TB and XDR-TB response plan 2007-2008. http://libdoc.who.int/hq/2007/WHO-HTM-TB-2007.387-eng.pdf. Accessed1 December 2008.
42. WHO. 2010. Multidrug and extensively drug-resistant TB (M/XDR-TB) 2010 global report on surveillance and response. http://whqlibdoc.who.int/ publications/2010/9789241599191-eng.pdf. Accessed 26 June 2010.
43. WHO. 2008. WHO media report. New rapid tests for drug-resistant TB for developing countries. http://www.who.int/mediacentre/news/releases/2008/pr21/en/ index.html. Accessed 9 September 2008.
44. WHO. 2006.WHOmedia report.WHOGlobal Task Force outlines measures to combat XDR-TB worldwide. http://www.who.int/mediacentre/news/notes/2006/np29/en/ index.html. Accessed 4 August 2007.
45. WHO. 2008. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. http://whqlibdoc.who.int/hq/2008/WHO-HTM-TB- 2008.392-eng.pdf. Accessed 08 September 2009.